117 related articles for article (PubMed ID: 28781022)
1. Determinants of Last-line Treatment in Metastatic Breast Cancer.
Cinausero M; Gerratana L; De Carlo E; Iacono D; Bonotto M; Fanotto V; Buoro V; Basile D; Vitale MG; Rihawi K; Fasola G; Puglisi F
Clin Breast Cancer; 2018 Jun; 18(3):205-213. PubMed ID: 28781022
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy in the last 30 days of life of advanced cancer patients.
Pacetti P; Paganini G; Orlandi M; Mambrini A; Pennucci MC; Del Freo A; Cantore M
Support Care Cancer; 2015 Nov; 23(11):3277-80. PubMed ID: 25900109
[TBL] [Abstract][Full Text] [Related]
4. Survival and Prognostic Factors of Metastatic Breast Cancer.
Laohavinij S; Paul V; Maneenil K
J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S16-26. PubMed ID: 29927171
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience.
Hussein MM; Gaafar RM; Abdel-Warith AM; Ahmed WA; Allahloubi NMA; Salem SE; Abdel-Salam IM
Clin Breast Cancer; 2017 Dec; 17(8):618-628. PubMed ID: 28625341
[TBL] [Abstract][Full Text] [Related]
6. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
Kassam F; Enright K; Dent R; Dranitsaris G; Myers J; Flynn C; Fralick M; Kumar R; Clemons M
Clin Breast Cancer; 2009 Feb; 9(1):29-33. PubMed ID: 19299237
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
9. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
10. Factors responsible for long-term survival in metastatic breast cancer.
Kontani K; Hashimoto S; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Date M; Teramoto K; Houchi H; Yokomise H
World J Surg Oncol; 2014 Nov; 12():344. PubMed ID: 25395387
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.
Bonotto M; Gerratana L; Di Maio M; De Angelis C; Cinausero M; Moroso S; Milano M; Stanzione B; Gargiulo P; Iacono D; Minisini AM; Mansutti M; Fasola G; De Placido S; Arpino G; Puglisi F
Breast; 2017 Feb; 31():114-120. PubMed ID: 27837704
[TBL] [Abstract][Full Text] [Related]
12. The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis.
Braga S; Miranda A; Fonseca R; Passos-Coelho JL; Fernandes A; Costa JD; Moreira A
Psychooncology; 2007 Sep; 16(9):863-8. PubMed ID: 17245696
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?
Bonotto M; Gerratana L; Iacono D; Minisini AM; Rihawi K; Fasola G; Puglisi F
Oncologist; 2015 Jul; 20(7):719-24. PubMed ID: 26018662
[TBL] [Abstract][Full Text] [Related]
14. Palliative Chemotherapy Near the End of Life in Oncology Patients.
Zhang Z; Chen ML; Gu XL; Liu MH; Zhao WW; Cheng WW
Am J Hosp Palliat Care; 2018 Sep; 35(9):1215-1220. PubMed ID: 29529885
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy use at the end of life. A retrospective single centre experience analysis.
Andreis F; Rizzi A; Rota L; Meriggi F; Mazzocchi M; Zaniboni A
Tumori; 2011; 97(1):30-4. PubMed ID: 21528660
[TBL] [Abstract][Full Text] [Related]
16. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer.
Mathew A; Achkar T; Abberbock S; Sandhu GS; Jacob ME; Villgran VD; Rosenzweig MQ; Puhalla S; Brufsky AM
Breast J; 2017 Nov; 23(6):718-722. PubMed ID: 28845536
[TBL] [Abstract][Full Text] [Related]
19. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
